ARTHUR KUAN, 29

CEO, COLD GENESYS

Arthur Kuan is going viral. He’s the CEO of Santa Ana, California, biotech company Cold Genesys, which genetically modifies viruses to attack cancer and, as an added benefit, bolsters your immune system against it. The former venture investor encountered Cold Genesys as a founding member at Hong Kong healthcare fund Ally Bridge Group. Fascinated by the science, Kuan, who holds a master’s in biotechnology from Johns Hopkins, joined Cold Genesys as COO. When founder Alex Yeung retired in 2016, Kuan took over. He’s since launched clinical trials of the biotech’s bladder cancer treatment and has inked a partnership to test its effectiveness with Merck’s immunotherapy drug Keytruda. Kuan says, “I’ve done a good job turning this science story into a real business concept.” In March he closed a $22 million series-C round with ORI Capital and Lepu Medical, which has the China license for its products. —Alex Knapp, Leah Rosenbaum